Surfactant Deficiency: Causes, Symptoms & Treatment
Surfactant deficiency occurs when the lungs produce insufficient surfactant, a substance vital for keeping the air sacs open, most commonly affecting premature newborns.
Things worth knowing about "Surfactant deficiency"
Surfactant deficiency occurs when the lungs produce insufficient surfactant, a substance vital for keeping the air sacs open, most commonly affecting premature newborns.
What is Surfactant Deficiency?
Surfactant deficiency is a condition in which the lungs do not produce enough surfactant -- a critical mixture of lipids and proteins that lines the inner surface of the alveoli (tiny air sacs in the lungs). Surfactant reduces surface tension in the alveoli, preventing them from collapsing after each breath. Without adequate surfactant, the alveoli collapse during exhalation, making breathing extremely difficult and potentially life-threatening.
Causes
The most common cause of surfactant deficiency is lung immaturity in premature infants. The specialized lung cells known as Type II pneumocytes, which are responsible for producing surfactant, are not fully mature before approximately 35 weeks of gestation.
- Premature birth: The greatest risk exists in newborns born before 28 weeks of gestation.
- Genetic defects: Rare mutations in the genes encoding surfactant proteins (SP-B, SP-C) can lead to congenital surfactant deficiency.
- Infant of a diabetic mother: Elevated insulin levels can inhibit surfactant maturation, increasing risk.
- Caesarean section without prior labor: Labor contractions stimulate surfactant production; their absence may delay lung maturation.
- Perinatal asphyxia: Oxygen deprivation during birth can impair surfactant synthesis and function.
Symptoms
Symptoms of surfactant deficiency appear immediately after birth or within the first few hours. The resulting condition is clinically referred to as Respiratory Distress Syndrome (RDS) of the newborn, also known as hyaline membrane disease.
- Rapid, shallow breathing (tachypnea)
- Chest wall retractions (sternal, intercostal, and subcostal) due to increased breathing effort
- Expiratory grunting -- an audible sound produced as the infant tries to maintain lung pressure
- Bluish discoloration of the skin and mucous membranes (cyanosis) due to low blood oxygen levels
- Nasal flaring as a sign of respiratory distress
Diagnosis
Diagnosis is based on clinical assessment supported by the following investigations:
- Chest X-ray: Reveals a characteristic ground-glass (reticulogranular) appearance and reduced lung aeration.
- Blood gas analysis: Measures oxygen and carbon dioxide levels in the blood to assess the severity of respiratory failure.
- Prenatal lung maturity testing: Analysis of amniotic fluid for the lecithin-to-sphingomyelin (L/S) ratio can estimate fetal lung maturity before delivery.
- Pulse oximetry: Continuous, non-invasive monitoring of blood oxygen saturation.
Treatment
Treatment of surfactant deficiency is carried out in a neonatal intensive care setting and includes several key approaches:
Surfactant Replacement Therapy
The most effective treatment is the direct administration of an exogenous surfactant preparation into the lungs via an endotracheal tube. Natural surfactant preparations derived from animal lungs (e.g., bovine or porcine) are commonly used. Administration can be prophylactic (immediately after birth) or therapeutic (after onset of respiratory distress).
Respiratory Support
- CPAP therapy (Continuous Positive Airway Pressure): Keeps the airways open using constant air pressure without requiring full mechanical ventilation.
- Mechanical ventilation: In severe cases, the infant is ventilated via an endotracheal tube connected to a mechanical ventilator.
Antenatal Prophylaxis
When preterm birth is anticipated, pregnant women are administered corticosteroids (e.g., betamethasone), which accelerate fetal lung maturation and can significantly reduce the severity of surfactant deficiency after birth.
Supportive Care
- Thermoregulation in an incubator to prevent hypothermia
- Intravenous fluid therapy to stabilize circulation and electrolyte balance
- Monitoring and treatment of associated complications such as intraventricular hemorrhage or necrotizing enterocolitis
Prognosis
Thanks to advances in neonatal intensive care and the introduction of surfactant replacement therapy, the prognosis for premature infants with surfactant deficiency has improved significantly. Mortality rates have declined substantially over recent decades. However, long-term complications such as chronic lung disease (bronchopulmonary dysplasia) or neurodevelopmental impairment remain possible, particularly in extremely preterm infants.
References
- Sweet DG et al. - European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2022 Update. Neonatology, 2023.
- Whitsett JA, Weaver TE - Hydrophobic Surfactant Proteins in Lung Function and Disease. New England Journal of Medicine, 2002; 347(26): 2141-2148.
- World Health Organization (WHO) - Born Too Soon: The Global Action Report on Preterm Birth. Geneva, 2012.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.